[go: up one dir, main page]

WO1999041368A3 - Optimization of immunomodulatory properties of genetic vaccines - Google Patents

Optimization of immunomodulatory properties of genetic vaccines Download PDF

Info

Publication number
WO1999041368A3
WO1999041368A3 PCT/US1999/003020 US9903020W WO9941368A3 WO 1999041368 A3 WO1999041368 A3 WO 1999041368A3 US 9903020 W US9903020 W US 9903020W WO 9941368 A3 WO9941368 A3 WO 9941368A3
Authority
WO
WIPO (PCT)
Prior art keywords
optimization
immunomodulatory properties
genetic vaccines
molecules
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/003020
Other languages
French (fr)
Other versions
WO1999041368A2 (en
Inventor
Juha Punnonen
Willem P C Stemmer
Robert Gerald Whalen
Russell Howard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Priority to MXPA00007889A priority Critical patent/MXPA00007889A/en
Priority to AU26741/99A priority patent/AU2674199A/en
Priority to EP99906948A priority patent/EP1053312A2/en
Priority to JP2000531549A priority patent/JP2002507392A/en
Priority to CA002320960A priority patent/CA2320960A1/en
Publication of WO1999041368A2 publication Critical patent/WO1999041368A2/en
Publication of WO1999041368A3 publication Critical patent/WO1999041368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention provides methods for obtaining molecules that can modulate an immune response, and immunomodulatory molecules obtained using the methods. The molecules find use, for example, in the tailoring of an immune response induced by a genetic vaccine for a desired purpose.
PCT/US1999/003020 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines Ceased WO1999041368A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA00007889A MXPA00007889A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines.
AU26741/99A AU2674199A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
EP99906948A EP1053312A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
JP2000531549A JP2002507392A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of gene vaccines
CA002320960A CA2320960A1 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2176998A 1998-02-11 1998-02-11
US7429498P 1998-02-11 1998-02-11
US60/074,294 1998-02-11
US09/021,769 1998-02-11

Publications (2)

Publication Number Publication Date
WO1999041368A2 WO1999041368A2 (en) 1999-08-19
WO1999041368A3 true WO1999041368A3 (en) 1999-12-16

Family

ID=26695070

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/003020 Ceased WO1999041368A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
PCT/US1999/003022 Ceased WO1999041369A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering
PCT/US1999/003023 Ceased WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US1999/003022 Ceased WO1999041369A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering
PCT/US1999/003023 Ceased WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors

Country Status (6)

Country Link
EP (3) EP1056842A2 (en)
JP (3) JP2002507392A (en)
AU (3) AU2674199A (en)
CA (3) CA2320960A1 (en)
MX (3) MXPA00007889A (en)
WO (3) WO1999041368A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821957B2 (en) 1997-05-20 2004-11-23 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
JP2002517995A (en) 1998-06-17 2002-06-25 マキシジェン， インコーポレイテッド Method for producing a polynucleotide having desired properties
AU5347999A (en) 1998-08-12 2000-03-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
WO2000020573A2 (en) 1998-10-07 2000-04-13 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
WO2000028018A1 (en) 1998-11-10 2000-05-18 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plant phenotypes
ATE439437T1 (en) 1999-01-05 2009-08-15 Univ Boston IMPROVED CLONING PROCESS
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
MXPA00009723A (en) * 1999-02-04 2003-09-22 Diversa Corp Non-stochastic generation of genetic vaccines and enzymes.
KR20010102069A (en) 1999-02-11 2001-11-15 추후제출 High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CA2379729A1 (en) 1999-07-22 2001-02-01 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
BR0012660A (en) 1999-07-22 2002-04-09 Procter & Gamble Protease variant of subtilisin type; cleaning composition; and personal care composition
BR0012693A (en) 1999-07-22 2002-04-09 Procter & Gamble Variant, of subtilisin-like protease; cleaning composition; and personal care composition
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
WO2001059071A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
AU5995701A (en) * 2000-05-26 2001-12-03 Univ Australian Synthetic peptides and uses therefore
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
JP2004513878A (en) 2000-06-23 2004-05-13 マキシジェン，　インコーポレイテッド Novel costimulatory molecules
EP1297146A2 (en) 2000-06-23 2003-04-02 Maxygen, Inc. Novel chimeric promoters
US20030165538A1 (en) * 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
DE10060959A1 (en) * 2000-12-06 2002-06-20 Aventis Res & Tech Gmbh & Co Processes for isolating and identifying effectors
DE60234159D1 (en) * 2001-02-02 2009-12-10 Large Scale Biology Corp METHOD OF INCREASING COMPLEMENTARITY IN A HETERODUPLEX POLYNUCLEOTIDE
US6723537B2 (en) 2001-05-18 2004-04-20 Rigel Pharmaceuticals, Incorporated Directed evolution of protein in mammalian cells
WO2003008436A2 (en) * 2001-07-19 2003-01-30 Icogen Corporation Methods for the identification of peptidyl compounds interacting with extracellular target molecules
CN100534436C (en) * 2001-11-21 2009-09-02 利兰·斯坦福青年大学托管委员会 polynucleotide
EP1572941A4 (en) 2002-02-26 2009-03-18 Maxygen Inc Novel flavivirus antigens
DK1493027T3 (en) 2002-03-01 2014-11-17 Codexis Mayflower Holdings Llc Methods, systems and software for identifying functional biomolecules
EP1488335A4 (en) 2002-03-09 2006-11-15 Maxygen Inc Optimization of crossover points for directed evolution
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US20040005604A1 (en) 2002-04-19 2004-01-08 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2494798A1 (en) 2002-08-06 2005-01-13 Verdia, Inc. Ap1 amine oxidase variants
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
EP3508578A1 (en) 2003-03-06 2019-07-10 BASF Enzymes, LLC Amylases, nucleic acids encoding them and methods for making and using them
CA3007908A1 (en) 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
EP1613733B1 (en) 2003-04-04 2015-06-03 BASF Enzymes LLC Pectate lyases, nucleic acids encoding them and methods for making and using them
MXPA05011585A (en) 2003-04-29 2006-05-25 Pioneer Hi Bred Int Novel glyphosate-n-acetyltransferase (gat) genes.
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP2404929B1 (en) 2003-07-02 2014-06-18 BP Corporation North America Inc. Glucanases, nucleic acids encoding them and methods for making and using them
EP1668113B1 (en) 2003-08-11 2013-06-19 Verenium Corporation Laccases, nucleic acids encoding them and methods for making and using them
DE602005023727D1 (en) 2004-06-09 2010-11-04 Pioneer Hi Bred Int PLASTIC TRANSIT PEPTIDE
CA2570872A1 (en) 2004-06-16 2006-01-26 Diversa Corporation Compositions and methods for enzymatic decolorization of chlorophyll
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20090038023A1 (en) 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
EP2949756A3 (en) 2005-03-15 2016-02-24 BP Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
WO2007092314A2 (en) 2006-02-02 2007-08-16 Verenium Corporation Esterases and related nucleic acids and methods
CA2637013A1 (en) 2006-02-10 2007-08-23 Verenium Corporation Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
WO2007095398A2 (en) 2006-02-14 2007-08-23 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
WO2007103389A2 (en) 2006-03-07 2007-09-13 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EP2388316A3 (en) 2006-03-07 2012-03-14 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
CN103397043A (en) 2006-08-04 2013-11-20 维莱尼姆公司 Glucanases, nucleic acids encoding same and method for making and using same
DK2617823T3 (en) 2006-09-21 2015-10-05 Basf Enzymes Llc Phytases, nucleic acids encoding them, and processes for their preparation and use
EA015591B1 (en) 2006-09-21 2011-10-31 Верениум Корпорейшн Phospholipases, nucleic acids encoding them and methods for making and using them
HUE033455T2 (en) 2006-12-21 2017-12-28 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them
EP2074136A4 (en) 2007-01-30 2012-11-07 Verenium Corp ENZYMES FOR THE TREATMENT OF LIGNOCELLULOSIC MATERIALS, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR THEIR MANUFACTURE AND USE
USRE46733E1 (en) 2007-10-03 2018-02-27 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
MX2010004883A (en) 2007-11-01 2010-11-10 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids.
CA2710922A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
EP2238242B9 (en) 2008-01-03 2015-06-10 BASF Enzymes LLC Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
AU2009248931A1 (en) 2008-05-23 2009-11-26 E. I. Du Pont De Nemours And Company Novel DGAT genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
BRPI0919113A2 (en) 2008-09-26 2016-08-09 Tocagen Inc isolated polynucleotide, substantially purified polypeptide, vector, host cell, recombinant reapply competent retrovirus, and methods for treating an individual with a proliferative cell disorder, and for treating a proliferative cell disorder in an individual
EP2698374B1 (en) 2009-05-21 2016-09-14 BASF Enzymes LLC Phytases, nucleic acids encoding them and methods for making and using them
IN2012DN01359A (en) 2009-08-20 2015-06-05 Pioneer Hi Bred Int
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
BR112012016290A2 (en) 2009-12-31 2015-09-01 Pioneer Hi Bred Int Isolated or recombinant nucleic acid, expression cassette, non-human host cell, transgenic plant and seed, isolated or recombinant oxox polypeptide variant, oxalate oxidase (oxox) protein level modulation method in a plant or plant cell, method for enhancing plant resistance to a pathogen, pathogen resistant plant, method to identify oxox variants with sustained or increased oxox activity, method to generate a plant that has increased resistance to a pathogen
AU2011289274B2 (en) 2010-08-13 2015-02-26 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity
WO2013166113A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
CA2904537A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
AU2014236154A1 (en) 2013-03-14 2015-09-17 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
MX360160B (en) 2013-03-15 2018-10-24 Pioneer Hi Bred Int PHI-4 POLYPEPTIDES and METHODS FOR THEIR USE.
WO2015023846A2 (en) 2013-08-16 2015-02-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
BR122020001770B1 (en) 2013-09-13 2022-11-29 Pioneer Hi-Bred International, Inc DNA CONSTRUCTION, METHOD FOR OBTAINING A TRANSGENIC PLANT, FUSION PROTEIN, METHOD FOR CONTROLLING AN INSECT PEST POPULATION, METHOD FOR INHIBITING THE GROWTH OR KILLING AN INSECT PEST
EP3102684B1 (en) 2014-02-07 2020-05-06 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
BR112016018287A2 (en) 2014-02-07 2017-10-10 Du Pont insecticide proteins and methods for their use
AU2015313650B2 (en) * 2014-09-11 2021-07-08 Vlp Therapeutics, Inc. Flavivirus virus like particle
RU2733898C2 (en) 2014-10-16 2020-10-09 Пайонир Хай-Бред Интернэшнл, Инк. Insecticidal proteins and methods of using them
RU2740312C2 (en) 2015-01-15 2021-01-13 Пайониэ Хай-Бред Интернешнл, Инк. Insecticidal proteins and methods for using them
EP3267796B1 (en) 2015-03-11 2023-08-09 Pioneer Hi-Bred International, Inc. Insecticidal combinations of pip-72 and methods of use
BR112017024948A2 (en) 2015-05-19 2018-07-31 Pioneer Hi Bred Int insecticide proteins and methods for their use
RU2762832C2 (en) 2015-08-06 2021-12-23 Пайонир Хай-Бред Интернэшнл, Инк. Insecticide proteins of plant origin and their application methods
US20180325119A1 (en) 2015-12-18 2018-11-15 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US11008585B2 (en) 2016-05-04 2021-05-18 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
JP6683847B2 (en) 2016-06-20 2020-04-22 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Strong and balanced bidirectional promoter
EP3478052B1 (en) 2016-07-01 2021-08-25 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
EP3535285B1 (en) 2016-11-01 2022-04-06 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3044404A1 (en) 2016-12-14 2018-06-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2018118811A1 (en) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MX2019009371A (en) 2017-02-08 2019-09-23 Pionner Hi Bred Int Inc Insecticidal combinations of plant derived insecticidal proteins and methods for their use.
BR112019023628A2 (en) 2017-05-11 2020-06-02 Pioneer Hi-Bred International, Inc. RECOMBINANT INSECTICIDE POLYPEPIDE, CHEMICAL INSECTICIDE PROTEIN, FUSION PROTEIN, AGRICULTURAL COMPOSITION, RECOMBINANT POLYNUCLEOTIDE, DNA BUILDING, TRANSGENIC PLANT, METHOD OF INHIBITING THE AGGREGATION OR EXERCISING AGAINST EXERCISE OR EXERCISE , METHOD TO CONTROL PEST INFESTATION AND METHOD TO IMPROVE THE PERFORMANCE OF A CULTURE
WO2019178038A1 (en) 2018-03-14 2019-09-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
US11525144B2 (en) 2018-03-14 2022-12-13 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
US20230051453A1 (en) 2020-01-10 2023-02-16 The Regents Of The University Of California Biosynthetic platform for the production of olivetolic acid and analogues of olivetolic acid
US12168774B2 (en) 2020-07-14 2024-12-17 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016027A1 (en) * 1993-12-06 1995-06-15 Bioinvent International Ab Method of selecting specific bacteriophages
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997035957A1 (en) * 1996-03-25 1997-10-02 Maxygen, Inc. Evolving cellular dna uptake by recursive sequence recombination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
AU6707194A (en) * 1993-04-19 1994-11-08 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
WO1994026787A1 (en) * 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Method for generating cell type specific phage antibody libraries
AU4010395A (en) * 1994-10-27 1996-05-23 Amgen, Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
CA2211993A1 (en) * 1995-01-31 1996-08-08 The Rockefeller University Identification of dec, (dentritic and epithelial cells, 205 kda), a receptor with c-type lectin domains, nucleic acids encoding dec, and uses thereof
EP0863704A4 (en) * 1995-09-28 2003-09-10 Univ Pittsburgh STIMULATION OF CELL-IMMUNED IMMUNE RESPONSE BY TARGETED SPECIAL GENETIC IMMUNIZATION
US6489145B1 (en) * 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016027A1 (en) * 1993-12-06 1995-06-15 Bioinvent International Ab Method of selecting specific bacteriophages
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997035957A1 (en) * 1996-03-25 1997-10-02 Maxygen, Inc. Evolving cellular dna uptake by recursive sequence recombination

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BENHAM A.M. & NEEFJES J.J.: "Proteasome activity limits the assembly f MHC class I molecules after IFN-gamma stimulation.", J. IMMUNOL., vol. 159, no. 2, 15 December 1997 (1997-12-15), pages 5896 - 5904, XP002117254 *
CONRY R M ET AL: "SELECTED STRATEGIES TO AUGMENT POLYNUCLEOTIDE IMMUNIZATION", GENE THERAPY, vol. 3, no. 1, 1 January 1996 (1996-01-01), pages 67 - 74, XP002035090, ISSN: 0969-7128 *
DAVIS H L ET AL: "DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice", VACCINE, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 849-852, XP004075668, ISSN: 0264-410X *
HOURVITZ A. ET AL.: "Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report", J. VIRAL HEPATITIS, vol. 3, 1996, pages 37 - 42, XP002117256 *
IRVINE K R ET AL: "CYTOKINE ENHANCEMENT OF DNA IMMUNIZATION LEADS TO EFFECTIVE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, vol. 156, 1 January 1996 (1996-01-01), pages 238 - 245, XP002030631, ISSN: 0022-1767 *
KLINMAN D.M. ET AL.: "Contribution of CpG motifs to the immunogenicity of DNA vaccines", J. IMMUNOLOGY, vol. 158, 1997, pages 3635 - 3639, XP002108454 *
KRIEGER M ET AL: "MOLECULAR FLYPAPER, ATHEROSCLEROSIS, AND HOST DEFENSE: STRUCTURE AND FUNCTION OF THE MACROPHAGE SCAVENGER RECEPTOR", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 57, 1 January 1992 (1992-01-01), pages 605 - 609, XP000561876 *
MARCO DI A ET AL: "AGONISTIC AND ANTAGONISTIC VARIANTS OF CILIARY NEUROTROPHIC FACTOR (CNTF) REVEAL FUNCTIONAL DIFFERENCES BETWEEN MEMBRANE-BOUND AND SOLUBLE CNTF ALPHA-RECEPTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 37, 12 September 1997 (1997-09-12), pages 23069 - 23075, XP002069814, ISSN: 0021-9258 *
PATTEN P A ET AL: "APPLICATIONS OF DNA SHUFFLING TO PHARMACEUTICALS AND VACCINES", CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 724 - 733, XP002916609, ISSN: 0958-1669 *
SAGGIO I ET AL: "CNTF VARIANTS WITH INCREASED BIOLOGICAL POTENCY AND RECEPTOR SELECTIVITY DEFINE A FUNCTIONAL SITE OF RECEPTOR INTERACTION", EMBO JOURNAL, vol. 14, no. 13, 1 January 1995 (1995-01-01), pages 3045 - 3054, XP002056939, ISSN: 0261-4189 *
SHEU S.Y. & LO S.J.: "Deletion or alteration of hydrophobic amino acids at the third transmembrane domains of Hepatitis B surface antigen enhances its production in Escherichia coli.", GENE, vol. 160, no. 2, 28 July 1995 (1995-07-28), pages 179 - 184, XP002117290 *
SHOUVAL D. ET AL.: "Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines", VACCINE, vol. 12, no. 15, November 1994 (1994-11-01), pages 1453 - 1459, XP002117255 *
XIANG Z ET AL: "MANIPULATION OF THE IMMUNE RESP0NSE TO A PLASMID-ENCODED VIRAL ANTIGEN BY COINOCULATION WITH PLASMIDS EXPRESSING CYTOKINES", IMMUNITY, vol. 2, no. 2, 1 February 1995 (1995-02-01), pages 129 - 135, XP000670098, ISSN: 1074-7613 *
ZOU J.J. ET AL.: "Structure-function analysis of the p35 subunit of mouse interleukin 12", J. BIOL.CHEM., vol. 270, no. 11, 17 March 1995 (1995-03-17), pages 5864 - 5871, XP002117289 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629170B2 (en) 1997-01-17 2009-12-08 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6821957B2 (en) 1997-05-20 2004-11-23 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7421347B2 (en) 1999-01-19 2008-09-02 Maxygen, Inc. Identifying oligonucleotides for in vitro recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7620502B2 (en) 1999-01-19 2009-11-17 Maxygen, Inc. Methods for identifying sets of oligonucleotides for use in an in vitro recombination procedure
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US7282334B2 (en) 2000-12-12 2007-10-16 Alligator Bioscience, Ab Method for in vitro molecular evolution of protein function
US7563578B2 (en) 2000-12-12 2009-07-21 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Also Published As

Publication number Publication date
MXPA00007891A (en) 2002-09-18
CA2320960A1 (en) 1999-08-19
MXPA00007893A (en) 2002-10-23
CA2320626A1 (en) 1999-08-19
JP2002507392A (en) 2002-03-12
WO1999041369A3 (en) 1999-09-23
CA2320431A1 (en) 1999-08-19
JP2002503461A (en) 2002-02-05
WO1999041402A3 (en) 1999-11-11
WO1999041369A2 (en) 1999-08-19
AU3291099A (en) 1999-08-30
JP2002503478A (en) 2002-02-05
EP1056842A2 (en) 2000-12-06
EP1053343A2 (en) 2000-11-22
AU2674299A (en) 1999-08-30
EP1053312A2 (en) 2000-11-22
WO1999041368A2 (en) 1999-08-19
MXPA00007889A (en) 2002-09-18
WO1999041402A2 (en) 1999-08-19
AU2674199A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
WO1999041368A3 (en) Optimization of immunomodulatory properties of genetic vaccines
WO2004075829A3 (en) Adjuvanted influenza vaccine
ATE454163T1 (en) BACTERIAL VACCINES CONTAINING AUXOTROPHIC ATTENUATE LISTERIA STRAINS WHICH EXPRESS HETEROLOGUE ANTIGENS
WO2004006837A3 (en) Mesothelin vaccines and model systems
AU2002355677A1 (en) Antigenic polypeptides
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO1999006544A8 (en) Membrane-bound cytokine compositions and methods of modulating an immune response using same
WO1999036544A3 (en) Neisseria meningitidis antigens
DE60335010D1 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHOD FOR STIMULATING AN IMMUNE RESPONSE
NO20001768D0 (en) Virus encapsulation vaccine, method of preparation and use thereof
AU2002365508A1 (en) Apparatus and method for modification of magnetically immobilized biomolecules
DE60141773D1 (en) GREAT SIMILAR RECEPTOR 5-LIGANDS AND USE PROCESS
EP1398379A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU2741295A (en) Method for preparing an influenza virus, antigens obtained and applications thereof
CY1107950T1 (en) NAVIGATION VACCINE COMPOSITIONS AND METHODS
DE60012042D1 (en) ENTEPNEUMOVIRUS AND APPROPRIATE VACCINE
WO2002062296A3 (en) Methods and compositions useful for stimulating an immune response
WO2004048552A3 (en) Modulating immune responses
WO2002024739A3 (en) Spas-1 cancer antigen
WO2003051288A3 (en) Mycobacterial vaccine
ZA200104189B (en) Method to produce inactivated w/o emulsion adjuvated vaccines.
WO2003049765A3 (en) Enveloped virus vaccine and method for production
EP1518927A3 (en) Optimization of immunomodulatory properties of genetic vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2320960

Country of ref document: CA

Ref country code: CA

Ref document number: 2320960

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 531549

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007889

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 26741/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999906948

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999906948

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999906948

Country of ref document: EP